Updates ·
Health notices · Wednesday 14 October
3 notices from the agencies today, in plain words, each with the original linked.
FDA approval for Synjardy (empagliflozin) with metformin
Food and Drug Administration (FDA) · Approval
If you have type 2 diabetes, the FDA has approved EMPAGLIFLOZIN as Synjardy (empagliflozin with metformin) to improve blood sugar control along with diet and exercise.
Synjardy contains an SGLT2 inhibitor (empagliflozin) and metformin (a biguanide). It is also intended to lower some risks in certain adults, including cardiovascular death and heart-failure hospitalization, and slow kidney disease progression.
This is for people with type 2 diabetes. It is not recommended to improve blood sugar in type 1 diabetes, and the notice says it may increase diabetic ketoacidosis risk in that setting.
Benzoyl Peroxide Wash recall for possible microbial contamination
FDA · Recall
If you used Benzoyl Peroxide Wash, USP 10% from Rugby Laboratories, this product is being recalled because of possible microbial contamination.
The FDA notice describes two bottle sizes and specific NDC numbers, and says it was distributed in Illinois only (published 2026-10-07).
If you have this product, check whether yours matches the recalled listings in the FDA notice.
FDA approval: duloxetine delayed-release capsules
FDA · Approval
If you are prescribed duloxetine delayed-release capsules, it is a serotonin and norepinephrine reuptake inhibitor (SNRI). An SNRI affects brain chemicals involved in mood and pain.
The label says it is indicated for major depressive disorder and generalized anxiety disorder, including for certain pediatric ages.
It is also indicated for diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain in adults, and fibromyalgia in certain pediatric ages.